Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increased serum glutamate in depressed patients.

Literature DB >> 6133511

Increased serum glutamate in depressed patients.

J S Kim, W Schmid-Burgk, D Claus, H H Kornhuber.

Abstract

Glutamate concentration was determined in serum from endogenous and neurotic depressive patients, in persons with schizophrenia or schizoaffective disorder, and in normal subjects. The mean serum glutamate level in the endogenous and neurotic depressive patients was found to be significantly higher than in any of the other groups. No other statistically significant differences were found. Statistical analysis revealed that the elevated serum glutamate concentration in the endogenous and neurotic depressive patients was probably caused by medication. These results are discussed in view of the effect of antidepressants upon the serum glutamate in the affective disorders.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1982 PMID： 6133511 DOI： 10.1007/bf00345492

Source DB: PubMed Journal: Arch Psychiatr Nervenkr (1970)

16 in total

1. Total and free tryptophan concentration in the plasma of depressive patients.

Authors: A Coppen; E G Eccleston; M Peet
Journal: Lancet Date: 1972-12-30 Impact factor: 79.321

2. Some remarks concerning the possible role of brain monoamines (dopamine, noradrenaline, serotonin) in mental disorders.

Authors: O Hornykiewicz
Journal: J Psychiatr Res Date: 1974 Impact factor: 4.791

3. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients.

Authors: J Mendels; A Frazer; R G Fitzgerald; T A Ramsey; J W Stokes
Journal: Science Date: 1972-03-24 Impact factor: 47.728

4. 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid.

Authors: H M van Praag; J Korf; J Puite
Journal: Nature Date: 1970-03-28 Impact factor: 49.962

5. Plasma amino acids as an index for subgroups in manic depressive psychosis: correlation to effect of tryptophan.

Authors: S E Moller; L Kirk; K H Fremming
Journal: Psychopharmacology (Berl) Date: 1976-09-17 Impact factor: 4.530

6. Total and non-bound tryptophan in unipolar illness.

Authors: G J Riley; D M Shaw
Journal: Lancet Date: 1976-12-04 Impact factor: 79.321

7. 5-Hydroxytryptamine in the hind-brain of depressive suicides.

Authors: D M Shaw; F E Camps; E G Eccleston
Journal: Br J Psychiatry Date: 1967-12 Impact factor: 9.319

8. "Serotonin depression"--a biochemical subgroup within the affective disorders?

Authors: M Asberg; P Thorén; L Träskman; L Bertilsson; V Ringberger
Journal: Science Date: 1976-02-06 Impact factor: 47.728

9. Biochemical post-mortem findings in depressed patients.

Authors: W Birkmayer; P Riederer
Journal: J Neural Transm Date: 1975 Impact factor: 3.575

10. Levels of total and free tryptophan in the plasma of endogenous and neurotic depressives.

Authors: W Schmid-Burgk; J S Kim; R Lischewski; W Rassmann
Journal: Arch Psychiatr Nervenkr (1970) Date: 1981

53 in total

Review 1. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors: Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal: Drugs Date: 2012-07-09 Impact factor: 9.546

Review 2. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors: Cagri Yüksel; Dost Öngür
Journal: Biol Psychiatry Date: 2010-08-21 Impact factor: 13.382

Review 3. Neuroinflammation and comorbidity of pain and depression.

Authors: A K Walker; A Kavelaars; C J Heijnen; R Dantzer
Journal: Pharmacol Rev Date: 2013-12-11 Impact factor: 25.468

Review 4. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors: Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal: Neuropharmacology Date: 2011-08-03 Impact factor: 5.250

Review 5. Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors: Xiaohua Li; Mark A Frye; Richard C Shelton
Journal: Neuropsychopharmacology Date: 2011-09-07 Impact factor: 7.853

6. Reduced GABAergic cortical inhibition in aging and depression.

Authors: Jennifer I Lissemore; Apoorva Bhandari; Benoit H Mulsant; Eric J Lenze; Charles F Reynolds; Jordan F Karp; Tarek K Rajji; Yoshihiro Noda; Reza Zomorrodi; Etienne Sibille; Zafiris J Daskalakis; Daniel M Blumberger
Journal: Neuropsychopharmacology Date: 2018-05-17 Impact factor: 7.853

7. Glutamatergic system abnormalities in posttraumatic stress disorder.

Authors: Daisuke Nishi; Kenji Hashimoto; Hiroko Noguchi; Kei Hamazaki; Tomohito Hamazaki; Yutaka Matsuoka
Journal: Psychopharmacology (Berl) Date: 2015-08-22 Impact factor: 4.530

Review 8. Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors: Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal: World J Psychiatry Date: 2016-03-22

Review 9. The As and Ds of stress: metabolic, morphological and behavioral consequences.

Authors: Lawrence P Reagan; Claudia A Grillo; Gerado G Piroli
Journal: Eur J Pharmacol Date: 2008-02-26 Impact factor: 4.432

10. Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors: Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal: Neuropsychopharmacology Date: 2012-10-17 Impact factor: 7.853